Psychedelic therapy

Heroic Dose Event Explores Promise of Psychedelic Medicine for Veterans, Military & Servicemen and Women

Thursday, April 8, 2021 - 1:00pm

Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .
  • The Heroic Dose will commence on 22nd April at 8:45 am EST.
  • This one-day virtual conference explores the use of psychedelic therapies for military veterans and first responders in an effort to combat the alarming rates of PTSD, substance abuse and suicide in this valuable yet underserved demographic.
  • This conference will feature some of the finest Navy SEAL and national security professionals, veterans and other servicemen and women, along with knowledgeable experts in psychedelic therapy, researchers, clinicians, companies, advocates.

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

Thursday, April 8, 2021 - 8:30am

Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.

Key Points: 
  • Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.
  • "We are extremely excited to strengthen our partnership with the team at ATMA through this investment.
  • ATMA's team is a true pioneer in the psychedelic therapy industry by growing a global network of group and retreat psychedelic therapy clinics," said Kelsey Ramsden, President and CEO, MINDCURE.
  • "We are thrilled today to welcome a visionary leader like Kelsey to our Board of Directors," said Vu Tran, Co-CEO of ATMA.

AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

Wednesday, April 7, 2021 - 2:00pm

The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.

Key Points: 
  • The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.
  • Anthony Hayes, CEO of AIkido Pharma, stated, "The novel homing peptides covered under this sublicense have the potential to allow the direct delivery of psilocybin to inflamed CNS tissue in cancer patients.
  • It complements our recently announced support of the psilocybin research for PTSD treatment at Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

Monday, March 29, 2021 - 2:00pm

NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").

Key Points: 
  • NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").
  • The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.
  • Each year, over 8.6 million adults grapple with PTSD, and nearly ten percent of Americans will experience PTSD at some time in their lives.
  • Currently, no academic institution, other than the Center, is conducting research involving the administration of psychedelics inside the VA System.

Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics

Monday, March 22, 2021 - 11:00am

PsyBioMed Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research and development company Natural MedTech.

Key Points: 
  • PsyBioMed Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research and development company Natural MedTech.
  • Medicallysupervised, legal access to evidence-based Psychedelic-Assisted Psychotherapy is becoming increasingly available through clinical trials for multiple conditions throughout Australia.
  • This research by the Australian government into whether psychedelic drugs are more effective than existing treatments sets the stage for large-scale clinical trials.
  • Natural MedTech conducts drug development, engages and supports clinical trials with the goal of advancing clinical application of psychedelics and other scheduled compounds of therapeutic relevance.

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

Monday, March 15, 2021 - 11:45am

VANCOUVER, BC, March 15, 2021 /PRNewswire/ -Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company's new Chief Operating Officer, effective immediately.

Key Points: 
  • VANCOUVER, BC, March 15, 2021 /PRNewswire/ -Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company's new Chief Operating Officer, effective immediately.
  • "I am thrilled to welcome Tarik to MINDCURE today," said Kelsey Ramsden, President & CEO, MINDCURE.
  • Mr. Lebbadi began his career as a software engineer and has extensive operational experience with technology platforms.
  • "I could not be more excited to join the MINDCURE team today," said Tarik Lebbadi, COO, MINDCURE.

Klarisana Expands Expertise and Vision with New Hires

Thursday, March 11, 2021 - 1:04pm

At Klarisana , we are proud to announce the arrival of our new Chief Behavioral Health Officer, Gladys Villa.

Key Points: 
  • At Klarisana , we are proud to announce the arrival of our new Chief Behavioral Health Officer, Gladys Villa.
  • Klarisana is also very proud to introduce Monica Sanchez, in her new role as Marketing Manager.
  • She is heavily involved in psychedelic research, education, and sharing her vision of a post-prohibitionist world.
  • Both Gladys and Monica bring to Klarisana their experience in health-positive practice procedures and messaging.

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

Tuesday, March 9, 2021 - 7:00am

NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs.

Key Points: 
  • NeonMind has engaged Mr. Martin to advise on drug development programs and recommend critical resources for execution, as well as review and evaluate potential drug development paths to advance NeonMind's two psilocybin drug development programs.
  • NeonMind's first drug candidate aims to use synthetic psilocybin to enhance a patient's ability to alter behaviours that cause weight loss through psychedelic-assisted cognitive therapy.
  • The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.
  • "Philippe will help us navigate the many decisions we need to make to advance synthetic psilocybin through the rigorous drug development process towards becoming an approved medical therapy."

ATMA Unveils Canada's First Psychedelic Journey Center, Offering 60 Acres of Immersive Healing and Transformation in the Foothills of the Rocky Mountains

Friday, February 19, 2021 - 5:26pm

David Harder, Co-CEO of ATMA, said: "Creekside Journey Center begins the exciting rollout of our plans to create immersive retreat-style Journey Centers across Canada and beyond.

Key Points: 
  • David Harder, Co-CEO of ATMA, said: "Creekside Journey Center begins the exciting rollout of our plans to create immersive retreat-style Journey Centers across Canada and beyond.
  • Our aim is to position ATMA as the disruptor in a psychedelic renaissance that is so often focused on up-scaling the therapy."
  • "ATMA will be known for finding a place you can connect, find healing, and discover community," he said.
  • Additional patients who have recently obtained Section 56 Exemptions are also scheduled to undergo legal psychedelic therapy with ATMA next week.

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World's First 'MDMA in Alcohol Use Disorder' Clinical Trial

Friday, February 19, 2021 - 1:59pm

Awakn to Advance Research into Phase IIb Trial

Key Points: 
  • Results published today in the Journal of Psychopharmacology, show that MDMA-Assisted Psychotherapy (3,4-methylenedioxymethamphetamine) was well tolerated by all participants.
  • Over an eight-week course of therapy, participants received two sessions with MDMA (187.5 mg each session).
  • Dr Ben Sessa, Awakn's Chief Medical Officer, commented, "This is the first clinical study into the potential effectiveness of MDMA-Assisted Psychotherapy as a treatment for Alcohol Use Disorder.
  • This was the world's first clinical research study exploring MDMA-Assisted Psychotherapy as a treatment for any addiction, and the results are promising.